Combination of PSMA Radiopharmaceuticals with Orthogonal Pharmacokinetics Improves Therapeutic Index in Castration-Resistant Prostate Cancer (EANM 2026) - Sep 29, 2026 - Abstract #EP-0193; "However, current [177Lu]Lu-PSMA-617 is limited by rapid pharmacokinetics, renal excretion, and reduced tumor retention... By leveraging the orthogonal pharmacokinetics of PSMA-617 and ART-101, the combination maintained high tumor absorbed dose while reducing normal-organ exposure, improving dose selectivity and therapeutic index. This cocktail represents a promising PSMA-targeted radiopharmaceutical strategy for prostate cancer."
PK/PD data • Castration-Resistant Prostate Cancer • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
|
|
J. Cabahug; M. Idrissou; R. Hernandez
|